Farber, Meike
Chen, Yiyang
Arnold, Lucas
Möllmann, Michael
Boog-Whiteside, Eva
Lin, Yu-An
Reinhardt, H. Christian
Dührsen, Ulrich
Hanoun, Maher
Funding for this research was provided by:
Dr. Werner Jackstädt-Stiftung
Universitätsklinikum Essen
Article History
Received: 4 May 2021
Accepted: 19 October 2021
First Online: 11 November 2021
Competing interests
: H.C.R. received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex Novartis, GSK and Merck. H.C.R. received research funding from BioNTech, Gilead and Astra-Zeneca. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing interest.